Fluoxetine and norfluoxetine serum concentrations and clinical response in weekly versus daily dosing

Psychopharmacology Bulletin

Volumn 32, Issue 1, 1996, Pages 27-32

  Burke, William J ^b   Hendricks, Shelton E ^b   McArthur Campbell, Delores ^b   Jacques, Daniel ^b   Stull, Todd ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NONE

Author keywords

depression; fluoxetine; norfluoxetine; serum concentrations; weekly dosing

Indexed keywords

FLUOXETINE; HALOPERIDOL; NORFLUOXETINE;

ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; FEMALE; HAMILTON SCALE; HUMAN; LONG TERM CARE; MALE; ORAL DRUG ADMINISTRATION; PHARMACOECONOMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; DEPRESSIVE DISORDER; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOXETINE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES;

EID: 0029948807     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Altamura, AC, and Montgomery, SA. Fluoxetine dose, pharmacokinetics and clinical efficacy. Rev. Contemp. Pharmacother. 1:75-81, 1990.
2. Amsterdam, JD; Hornig-Rohan, M; Rosenbaum, JF; Quitkin, FM; Fawcett, J; Reimherr, FW; and Beasley, CM. Fluoxetine and norfluoxetine plasma levels in major depression (Abstract). Biol. Psychiatry 37:606, 1995.
3. Beasley, CM; Bosomworth, JC; and Wernicke, JF. Fluoxetine: Relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacol. Bull. 26:18-24, 1990.
4. Burke, WJ; Hendricks, SE; McArthur-Campbell, D; Jacques, D; Bessette, D; McKillip, T; Stull, T; and Wilson, J. Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: Results of a placebo-controlled, randomized clinical trial. Unpublished manuscript.
5. Cain, JW. Poor response to fluoxetine: Underlying depression, serotonergic overstimulation, or a "therapeutic window"? J. Clin. Psychiatry 53:272-277, 1992.
6. DeVane, CL. Pharmacokinetics of the newer antidepressants: Clinical relevance. Am. J. Med. 97(6A):13S-23S, 1994.
7. Frank, E; Kupfer, DJ; Perel, JM; Cornes, C; Mallinger, AG; Thase, ME; McEachran, AB; and Grochocinski, VJ. Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression. J. Affect. Disord. 27:139-145, 1993.
8. Goodnick, PJ. Pharmacokinetics of second generation antidepressants: Fluoxetine. Psychopharmacol. Bull. 27:503-512, 1991.
9. Gram, LF. Fluoxetine. N. Engl. J. Med. 331:1354-1361, 1994.
10. Hamilton, M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23:56-62, 1960.
11. Kelly, MW; Perry, PJ; Holstad, SG; and Garvey, MJ. Serum fluoxetine and norfluoxetine concentrations and antidepressant response. Ther. Drug Monit. 11:165-170, 1989.
12. Montgomery, SA; Baldwin, D; Shah, A; Green, M; Fineberg, N; and Montgomery, D. Plasma-level response relationships with fluoxetine and zimelidine. Clin. Neuropharmacol. 13(1):71S-75S, 1990.
13. Montgomery, SA; Dufour, H; Brion, S; Gailledreau, J; Laqueille, X; Ferrey, G; Moron, P; Parant-Lucena, N; Singer, L; Danion, JM; Beuzen, JN; and Pierredon, MA. The prophylactic efficacy of fluoxetine in unipolar depression. Br. J. Psychiatry 153(Suppl.):69-76, 1988.
14. National Institute of Mental Health. Special feature: Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol. Bull. 21(4), 1985.
15. Norman, TR; Gupta, RK; Burrows, GD; Parker, G; and Judd, FK. Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine. Int. Clin. Psychopharmacol. 8:25-29, 1993.
16. Pato, MT; Murphy, DL; and DeVane, CL. Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation. J. Clin. Psychopharmacol. 11:224-225, 1991.
17. Perez-Sola, V; Perez-Blanco, J; Alvarez, E; and Queralto, JM. Plasmatic concentrations of fluoxetine, pharmacokinetics, therapeutic response and side effects. Acta Luso-Esp. Neurol. Psiquiatr. Cienc. Afines 21:143-147, 1993.
18. Preskorn, SH, and Magnus, RD. Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors: In vitro and in vivo findings and their implications for patient care. Psychopharmacol. Bull. 30:251-259, 1994.
19. Preskom, SH; Silkey, B; Beber, J; and Dorey, C. Antidepressant response and plasma concentrations of fluoxetine. Ann. Clin. Psychiatry 3:147-151, 1991.
20. Prien, RF, and Kocsis, JH. Long-term treatment of mood disorders. In: Bloom, FE, and Kupfer, DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, 1995. pp. 1067-1079.
21. SAS Institute, Inc. SAS User's Guide, Version 6.0. Gary, NC: SAS Institute, Inc. p. 952.
22. Tollefson, GD; Greist, JH; Jefferson, JW; Heiligenstein, JH; Sayler, ME; Tollefson, SL; and Koback, K. Is baseline agitation a relative contraindication for a selective serotonin reuptake inhibitor? A comparative trial of fluoxetine versus imipramine. J. Clin. Psychopharmacol. 14:385-391, 1994.
23. van Harten, J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin. Pharmacokinet. 24:203-220, 1993.
24. Wernicke, JF; Dunlop, SR; Dornseif, BE; Bosomworth, JC; and Humbert, M. Low-dose fluoxetine therapy for depression. Psychopharmacol. Bull. 24:183-188, 1988.
25. Wernicke, JF; Dunlop, SR; Dornseif, BE; and Zerbe, RL. Fixed-dose fluoxetine therapy for depression. Psychopharmacol. Bull. 23:164-168, 1987.
26. Wong, SH; Dellafera, SS; and Fernandes, R. Determination of fluoxetine and norfluoxetine by high-performance liquid chromatography. J. Chromatogr. 499:601-608, 1990.